Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Share-based Compensation (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Share-based Compensation for 12 consecutive years, with $2.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation rose 112.92% year-over-year to $2.2 million, compared with a TTM value of $4.8 million through Sep 2025, up 17.39%, and an annual FY2024 reading of $4.4 million, up 28.85% over the prior year.
  • Share-based Compensation was $2.2 million for Q3 2025 at Sanara MedTech, up from $130174.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.2 million in Q3 2025 and bottomed at $130174.0 in Q2 2025.
  • Average Share-based Compensation over 5 years is $887828.0, with a median of $803386.0 recorded in 2024.
  • The sharpest move saw Share-based Compensation skyrocketed 242.62% in 2021, then tumbled 90.78% in 2025.
  • Year by year, Share-based Compensation stood at $1.8 million in 2021, then plummeted by 59.76% to $731096.0 in 2022, then rose by 17.71% to $860559.0 in 2023, then surged by 38.94% to $1.2 million in 2024, then skyrocketed by 82.6% to $2.2 million in 2025.
  • Business Quant data shows Share-based Compensation for SMTI at $2.2 million in Q3 2025, $130174.0 in Q2 2025, and $1.3 million in Q1 2025.